LncRNAs have recently emerged to influence the pathogenesis of fragile X syndrome (FXS), which is caused by the functional loss of fragile X mental retardation protein (FMRP). However, the interaction between FMRP and lncRNAs on regulating neuronal development remains elusive. Here, we reported that FMRP directly interacted with lncRNA TUG1, and decreased its stability. Furthermore, TUG1 bond to transcriptional regulator, SnoN, and negatively modulated SnoN-Ccd1 pathway to specifically control axonal development. These observations suggested interplay between FMRP and lncRNAs might contribute to the pathogenesis of FXS.
Introduction
Fragile X syndrome (FXS), one of the most common forms of inherited intellectual disability, is caused by the functional loss of fragile X mental retardation protein (FMRP) (1, 2) . Extensive research efforts have focused on elucidating the functional roles of FMRP on neuronal dendrite and spine development and synaptic plasticity to uncover the pathogenesis of FXS (1, (3) (4) (5) . However, our understanding of the underlying mechanisms of FMRP regulating axonal development is very limited.
FMRP is an RNA-binding protein that is encoded by Fmr1 gene. Extensive studies suggest FMRP acts as a translational repressor to regulate protein synthesis by directly binding to its target mRNAs (4, (6) (7) (8) (9) , including MAP1b and CaMKIIa, which are required for neuronal development. Moreover, FMRP is biochemically and genetically involved in the microRNA pathway (10) , and the FMRP-associated miRNAs have been known to regulate neuronal development (11, 12) , which suggest the interaction between FMRP and non-coding RNA contributes to the pathogenesis of FXS. Long non-coding RNAs (lncRNAs) are a heterogeneous group of non-coding transcripts more than 200 nt long that are involved in many human diseases (13, 14) . Accumulating evidences suggest that the etiology of FXS is influenced by lncRNAs (15) . Previously, it has been suggested that FMRP can directly bind to non-coding RNA BC1, and modulate FMRP-targeted mRNA translation (16, 17) . Later, the contradictory result has been reported (18) . So far, the associations between FMRP and mRNA, or microRNA have been intensively studied on neuronal development. However, the interaction between FMRP and lncRNAs to regulate neuronal development is still elusive. In this study, we found FMRP directly interacted with lncRNA TUG1, and decreased its stability. Furthermore, TUG1 bond to the transcriptional regulator, SnoN and inhibited its transcriptional activity, which in turn modulated SnoN-Ccd1 pathway to specifically regulate axonal development.
Results

FMRP regulates both dendrite and axon development
We firstly transfected cultured hippocampal neurons with Fmr1 shRNA, which is validated in our previous studies (19, 20) , to assess if FMRP regulate neuronal axon development. Consistent with our previous findings (19) (20) (21) , Fmr1 shRNA efficiently knocked down FMRP expression (Supplementary Material, Fig.  S1A ) and FMRP-deficient neurons displayed shorter dendrites and reduced dendritic complexity, compared with the control neurons ( Fig. 1A-C) . Interestingly, FMRP-deficient neurons also exhibited shorter axons, revealing by Tau1 staining ( Fig. 1D and E), which suggested FMRP is required for axon development in vitro. To address the role of FMRP on axon growth in vivo, we electroporated Fmr1 shRNA into the cerebral cortex of E15.5 embryos, and then assessed at postnatal day 3. Fmr1-deficient neurons exhibited axonal outgrowth defect during cortex development ( Fig. 1F and G) , which might not be owing to the effects of FMRP deficiency on extended trailing processes/axon formation during brain development (22, 23) . Taking together, the above data suggested that FMRP is required for axon outgrowth both in vitro and in vivo.
FMRP binds to and regulates lncRNA TUG1 expression
To assess whether FMRP regulates lncRNAs expression, we firstly compared the lncRNAs expression profile between Fmr1 KO and WT hippocampus using real-time PCR-based lncRNA arrays. Among the lncRNAs with >2-fold changes in Fmr1 KO hippocampus comparing to WT ( Fig. 2A) , FMRP directly bond to TUG1, but not to Rian, Six3os and Dlxas in N2a cells (Fig. 2B ) and WT hippocampi (Supplementary Material, Fig. S1B ) by using RNA-immunoprecipitation. Furthermore, biotin-labeled synthetic TUG1 sense RNA could pulldown FMRP, whereas the TUG1 antisense RNA did not (Fig. 2C) . We further confirmed that knockdown of Fmr1 expression indeed led to increased TUG1 expression using real-time PCR assay (Fig. 2D) , which suggested FMRP negatively regulated TUG1 expression through physically interacting with it.
Using fluorescent in situ hybridization (FISH), we found TUG1 was expressed in the nucleus, as well as in the neuronal soma, dendrites and axon (Fig. 2F , and Supplementary Material, Fig. S2 ). Since FMRP is highly expressed in neuronal soma, dendrite and axon, this led us to hypothesize the elevated TUG1 expression levels in FMRP-deficient cells might be owing to increase RNA stability. Therefore, we treated FMRP-deficient and control cells with actinomycin D to inhibit gene transcription and assessed the TUG1 RNA levels over a 10-h period. Comparing to control cells, FMRP-deficient cells had a longer half-life of TUG1 RNA (Fig. 2E) , which suggested FMRP regulated TUG1 expression through decreasing its stability.
TUG1 specifically regulates axonal development TUG1 has been known to highly express in the brain and retina, and is required for the proper formation of photoreceptors in the developing retina (24) . To investigate the functional role of TUG1 on neuronal development, we performed TUG1 gain-offunction (GOF) and loss-of-function (LOF) analysis on culture hippocampal neurons to assess neuronal development. Firstly, we found overexpression of TUG1 did not significantly impair dendritic length and dendritic complexity (Fig. 3A-D) . Next, we generated two TUG1 shRNA constructs, which were significantly knocked down endogenous TUG1 expre ssion (Fig. 3E) . Interestingly, knockdown of TUG1 expression either had no significant effect on dendritic length and complexity (Fig. 3F-H) . Therefore, our GOF and LOF analyses suggested that TUG1 is dispensable for dendrite development.
However, we found knockdown of TUG1 expression slightly promoted axon development in cultured hippocampal neurons ( Fig. 4A and B) . On the other hand, overexpression of TUG1 led to significantly reduced axonal length ( Fig. 4C and D) . Since FMRP deficiency resulted in up-regulation of TUG1, we therefore performed in vivo analysis to assess if overexpression of TUG1 impairs axon development. We then electroporated TUG1 overexpression plasmid into the cerebral cortex of E15.5 embryos and assessed at postnatal day 3. TUG1-overexpressing neurons exhibited axonal outgrowth defects during cortex development ( Fig. 4E and F) , which mimicked axonal growth defect in FMRPdeficient neurons in vivo. Therefore, above data suggested interaction between FMRP and TUG1 specifically regulated axonal development.
Knockdown of TUG1 expression rescues axonal development defect in FMRP-deficient neurons Next, we investigated whether knockdown of TUG1 expression could rescue axon growth deficits caused by FMRP deficiency. We firstly knocked down TUG1 expression in cultured FMRPdeficient hippocampal neurons, and found knockdown of TUG1 expression in FMRP-deficient neurons significantly increased axonal length to the levels of control neurons ( Fig. 5A and B) . To consolidate the rescue effect of TUG1 knockdown on FMRPdeficient neuron in vivo, we co-electroporated TUG1 shRNA together with Fmr1 shRNA into the cerebral cortex of E15.5 embryos, and then assessed at postnatal day 3. Consistent with our in vitro findings, knockdown of TUG1 expression in FMRPdeficient neurons led to significantly increased axonal length to the level of control neurons during cerebral cortex development ( Fig. 5C and D) .
TUG1 regulates axonal development through mediating the SnoN-Ccd1 pathway SnoN, a transcriptional regulator, has been known to specifically control axon growth through regulating the expression of the actin binding protein Ccd1 (25, 26) . Our above data showed that TUG1 was also expressed in the nucleus of neurons (Fig. 2F , and Supplementary Material, Fig. S2 ), we then hypothesized that TUG1 might interact with SnoN to specifically regulate axon development. Using RNA pull-down assay, we found biotin-labeled synthetic TUG1 co-immoprecipitated with SnoN ( Fig. 6A) , which suggested that TUG1 is physically associated with SnoN. However, we found knockdown of Fmr1 or overexpression of TUG1 did not affect the total protein expression level of SnoN ( Fig. 6B and C) . To test if SnoN transcriptional activity is affected in FMRP-deficient or TUG-overexpressing cells, we then performed Ccd1 promoter activity assay using a luciferase reporter gene that is controlled by the Ccd1 promoter (Ccd1-luciferase). Both knockdown of Fmr1 and overexpression of TUG1 led to significant decreased the expression of Ccd1-luciferase reporter gene ( Fig. 6D and E) . Moreover, knockdown of TUG1 expression rescued Ccd1-luciferase reporter gene expression of FMRPdeficient cells to the level of control cells (Fig. 6F) . Next, both knockdown of Fmr1 and overexpression of TUG1 resulted in decreased the expression levels of Ccd1 mRNA and Ccd1 protein ( Fig. 6G and H, and Supplementary Material, Fig. S3 ). Furthermore, knockdown of TUG1 expression could rescue Ccd1 mRNA expression of FMRP-deficient cells to the level of control cells (Fig. 6I) . However, Ccd1 down-regulation in FMRP-deficient cells was not owing to alter Ccd1 mRNA stability (Fig. 6J ).
Collectively, these data suggested that interplay between FMRP and TUG1 regulated SnoN transcriptional activity.
Next, we investigated whether reintroduction of Ccd1 expression could rescue axon growth defects in FMRP-deficient or TUG1 overexpression neurons. Compared with the control neurons, Ccd1 overexpression led to increased axonal length ( Fig. 6K and L), which is consistent with previous studies that SnoN-Ccd1 activation promotes axon growth (25, 26) . Moreover, overexpression of Ccd1 rescued axonal length of FMRP-deficient or TUG1-overexpressing neurons to the levels of control neurons ( Fig. 6K and L) . Taking together, these data suggested that interaction between FMRP and lncRNA TUG1 regulated axonal development through mediating SnoN-Ccd1 pathway.
Discussion
FXS is caused by an expansion of a CGG repeats in the promoter region of Fmr1 gene, which leads to silencing of the gene by methylation of CGG repeat and resulting in loss of FMRP protein expression. LncRNA FMR5 and FMR6 are two new transcripts in the Fmr1 gene locus. FMR5 was expressed in several human brain regions from full and premutation patients, whereas FMR6 was silenced in both full mutation and in premutation carriers (27) . The functional implication of FMR5/6 in FXS is still need to be elucidated. LncRNA FMR4 and FMR1-AS are transcribed in the antisense orientation by the bidirectional promoter of Fmr1 (28, 29) . FMR4 is silenced in FXS patients and upregulated in premutation carriers (29) . However, FMR1-AS is silenced in FXS patients by an independent mechanism from FMRP, and is implicated in fragile X-associated tremor/ataxia syndrome (FXTAS), which is a neurodegenerative disorder caused by premutation CGG repeat expansion (55-200 repeats) within the 5 0 UTR of the Fmr1 gene (28, 30) .
Loss of FMR1-AS expression leads to alteration of cell cycle progression and apoptosis (29) . However, the underlying mechanisms of FXTAS pathogenesis are still unclear, and many questions are opened to be answered. In addition to alteration of lncRNA expression owing to methylation of bidirectional promoter of Fmr1 gene, FMRP, as an RNAbinding protein, has been known to bind to non-coding RNA BC1 and form a FMRP-BC1 complex to repress translation of a defined subset of FMRP target mRNAs in neurons. However, the mechanism of FMRP's interaction with lncRNAs has remained controversial (18) . Therefore, the functional role of the physical interaction between FMRP and lncRNAs on neuronal development is not fully understood yet. Previous study suggested that there is a significant correlation of interaction between FMRP and lncRNA TUG1 across many cancer types (31) . In addition, the presynaptic localization of FMRP has been demonstrated in the central never system (38) . FMRP mediates the axonal delivery microRNA, miR181d and negatively regulates axon development by locally targeting the transcriptions of Map1b and Calm1. In our study, combining biochemical experiments with cell biology and in vivo studies, we found that FMRP regulates axon development through directly interacting with lncRNA TUG1. During cerebral cortex development, FRMP has been known to regulate multipolar-to-bipolar transition in the cortical plate during embryonic development, while not affecting extended trailing processes/axon formation of migratory neurons (22, 23) . Although we cannot completely rule out the possibility of neuronal positioning defects affecting axon outgrowth in FXS mouse model, our in vitro and in vivo data suggested FMRP is required for axonal development. The precise molecular mechanisms underlying FMRP regulating neuronal development through non-coding RNAs required further investigation.
The underlying mechanisms of regulating SnoN function in postmitotic neurons are beginning to be elucidated. Previous studies demonstrated that the ubiquitin ligase Cdh1/APC promotes the ubiquitination and subsequent degradation of SnoN, and thereby inhibits axonal growth (26, 32) . We found that knockdown of Fmr1 or overexpression of TUG1 did not affect the overall protein expression level of SnoN, which suggested interplay between FMRP and TUG1 regulates SnoN activity might not through the ubiquitin-proteasome system. LncRNAs can regulate gene expression by binding specific transcriptional factors to inhibit or enhance the activity of specific transcription factors (33) . We found TUG1 repressed SnoN transcriptional activity through binding to it, and led to decreased Ccd1 expression, the wellknown SnoN-targeted gene. Thus, our data provided an alternative underlying mechanism of regulating SnoN activity by lncRNA TUG1. Actin cytoskeleton remodeling plays important roles in dendritic spine morphogenesis, and axon growth (34, 35) . FMRP deficiency leads to a high density of long, thin and immature dendritic spines (36, 37) , and impaired axon outgrowth as well (12, 38) . Recent studies suggest FMRP regulates dendritogenesis and spinogenesis through controlling actin cytoskeleton dynamics by interfering with Rac1 pathway and Rho-signaling (39, 40) . In this study, we found that FMRP regulates axonal development through mediating Ccd1 expression. Ccd1 has been found to localize to the actin cytoskeleton and enrich at the axon terminals in neurons (25) . As a DIX domain protein, Ccd1 has been known to be involved in Wnt signaling (41) . Therefore, it will be interesting to determine the underlying mechanisms of FMRP regulating actin cytoskeleton by which to control axon development.
Materials and Methods
Mice and cell line
All animal procedures were performed according to protocols approved by the Institute of Genetics and Developmental Biology, CAS, Care and Use Committee. The Fmr1 KO mice bred on the C57B/L6 genetic background was as described previously (20) . 
Mouse primary neuron isolation and transfection
Hippocampal neurons were isolated and transfected as described previously (20) . Hippocampal neurons from wild-type P0 neonate mice were grown as dispersed mixed cell cultures. Hippocampal neurons were transfected on Day 1 (DIV 1) for axonal morphogenesis or on Day 4 (DIV 4) for dendritic morphogenesis. Transfection was performed as described using Lipofectamine 2000 (Life technologies). At 48 or 72 h after transfection, the neurons were fixed and stained as described below.
Immunocytochemistry
Neurons were washed with PBS and fixed with 4% paraformaldehyde. After fixation, cells were washed with PBS and preblock using PBS containing 5% normal goat serum and 0.1% Triton X-100, followed by overnight incubation with primary antibodies: mouse anti-Tau1(1:1000, Merck Millipore, MAB3420) and rabbit anti-Map2 (1:1000, Sigma-Aldrich, M3696). After washing with PBS, cells were incubated with secondary antibodies that included donkey anti-mouse 568 and donkey anti-rabbit 647, and followed by counterstaining with the DAPI. The coverslips were mounted with VECTASHIELD (VECTOR, H-1000).
In uterus electroporation and tissue processing
In utero electroporation was performed as previously described (42, 43) . Timed pregnant females were anesthetized, and their uterine horns were exposed with a midline laparotomy incision. Embryos were removed and carefully placed on humidified gauze pads. Plasmid DNA plus Fast Green (Fluka) was injected into the lateral ventricle of the embryonic brain with a glass micropipette. For electroporation, 5 Â 50 ms, 37 V square pulses separated by 950 ms intervals were delivered with forceps-type electrodes connected to an ECM 830 electroporator (BTX Harvard Apparatus). The uteri were then returned to the abdominal cavity, and the abdomen wall and skin were sutured using a surgical needle and thread. The whole procedure was completed within 40 min. The pregnant mouse was warmed in an incubator until it regained consciousness, and embryos were allowed to develop in utero for the time indicated. For brain tissue processing, the brains were fixed in 4% PFA overnight at 4 C, placed in 30% sucrose in PBS for 2 days, and frozen for sectioning using a Leica cryostat. The axon length quantification was performed as previous described (44) . The extending axons were measured by taking the edge of the GFP labeled region as the starting point.
Actinomycin D treatment and mRNA stability assay N2a were treated with 10 mg/ml of actinomycin D (SigmaAldrich) to inhibit gene transcription as described (20, 45) and cells were collected at various time intervals for RNA isolation and real-time PCR analysis. TUG1 RNA levels were normalized to GAPDH.
RT-PCR, real-time PCR and pathway arrays
RT-PCR and real-time PCR were performed using standard methods as described (45) . The first-strand cDNA was generated by reverse transcription with oligo (dT) primer or random hexamers. Standard RT-PCR was performed using GoTaq DNA polymerase (Promega). To quantify the mRNA levels using real-time PCR, aliquots of first-stranded cDNA were amplified with genespecific primers and Power SYBR Green PCR Master Mix (Applied Biosystems) using a
Step-1 Real-Time PCR System (Applied Biosystems). The PCR reactions contained 20-40 ng of cDNA (except the cDNA for the IP, for which 5% of the cDNA was used for each gene examined), Universal Master Mix (Applied Biosystems), and 300 nM of forward and reverse primers in a final reaction volume of 20 ll. The ratio of different samples was calculated by the data analysis software built in with the Step-one Real-Time PCR System. To determine differential gene expression, cDNA were synthesized from isolated RNA, and 40 ng cDNA was added into each well of a 96-well pre-manufactured mouse lncRNA Array (Qiagen/SABioscience). Real-time PCR and data analyses were performed according to the manufacturer's instruction (Qiagen/ SABioscience). Briefly, the expression level of each gene was obtained by comparing to internal controls on the same array. The relative expression levels of genes in experimental group compared with control group were then calculated with control samples set as '1'.
The sequences of primers used for RIP-PCR reactions are as the following:
RNA immunoprecipitation
RNA-IP was performed as described (20, 45) . Briefly, cells were harvested and homogenized in 1 ml of ice-cold lysis buffer [10 mM Hepes (pH 7.4), 200 mM NaCl, 30 mM EDTA and 0.5% Triton X-100] with 2Â complete protease inhibitors (BoehringerMannheim). Nuclei and debris were pelleted at 3000g for 10 min; the supernatant was collected and raised to 300 mM NaCl, and clarified at 14 000g for 30 min. The resulting supernatant was pre-cleared for 1 h with 100 ll recombinant protein G agarose (Invitrogen) (washed with lysis buffer first). An aliquot of precleared input was saved for RNA extraction (200 ll) and protein analysis (100 ll). A monoclonal antibody against FMRP (F1554, Sigma) was incubated with recombinant protein A dynabeads at 4 C for 2 h and washed three times with lysis buffer. RNase Inhibitors (Roche) was added to the remaining lysates. The precleared lysates were immunoprecipitated with antibody-coated recombinant protein G agarose at 4 C for 2 h. After third wash with the lyses buffer, 10% of immunoprecipitate was saved for protein analysis. The remaining was washed one more time and the immunoprecipitate was re-suspended into Trizol (Invitrogen) for RNA isolation.
In vitro transcription of biotin-labeled TUG1 RNA and binding assay
This procedure was carried as previously published (20, 45) . Briefly, the pCRII-TOPO vector containing TUG1 fragments as described above was linearized using HindIII or SpeI restriction enzymes to create anti-sense or sense templates for in vitro transcription. To generate biotin-labeled TUG1 fragment, linearized vectors were in vitro transcribed using AmpliScritbeTM T7-FlashTM biotin-RNA transcription Kit (ASB71110, Epicentre Biotechnologies). To determine whether synthetic biotinylated TUG1 RNA fragments could bind endogenous FMRP or SnoN, protein lysate was prepared by homogenizing mouse hippocampi using RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). Then, 30 lg of purified biotinylated TUG1 transcripts were incubated with 500 lg of total protein in the binding buffer (10 mM HEPES, pH by biotinylated TUG1 RNA fragments, the beads were washed three times with 1Â binding buffer and resuspended in 1Â binding buffer with SDS gel loading dye to dissolve protein bound to biotinylated TUG1 RNA fragments. The proteins in the pulldown material were separated by 4-20% SDS-PAGE gel, transferred to nitrocellulose membrane for Western blot analysis using mouse anti-FMRP (1:1000, EMD Millipore, MAB2160) or rabbit anti-SnoN antibody (1:500, Bioss, bs-5945R).
Western blotting analyses
Protein samples were separated on SDS-PAGE gels (Bio-Rad) and then transferred to PVDF membranes (Millipore). Mouse anti-FMRP (1:1000, EMD Millipore, MAB2160) and rabbit anti-Ccd1 (1:500, Bioss, bs-14334R) were used as primary antibodies. Horseradish peroxidase-conjugated secondary antibodies were obtained from Bioss. For loading controls, membranes were stripped and reprobed with the mouse antibody against b-actin (1:2000, Sigma-Aldrich, A5441).
Statistical analysis
Statistical analysis was performed using ANOVA and Student's t test, unless specified, with the aid of SPSS version 17. All percentages were arcsine-transformed before statistical analysis. We first normalized the treatment group by the control group for RT-PCR, and then one-sample t test against mean of 1 was used on the normalized values. All data were shown as mean with standard error of mean (mean 6 SEM). Probabilities of P < 0.05 were considered as significant.
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